Correlation Between Inhibikase Therapeutics and Blueprint Medicines
Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibikase Therapeutics and Blueprint Medicines Corp, you can compare the effects of market volatilities on Inhibikase Therapeutics and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and Blueprint Medicines.
Diversification Opportunities for Inhibikase Therapeutics and Blueprint Medicines
0.49 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Inhibikase and Blueprint is 0.49. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and Blueprint Medicines go up and down completely randomly.
Pair Corralation between Inhibikase Therapeutics and Blueprint Medicines
Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 2.27 times more return on investment than Blueprint Medicines. However, Inhibikase Therapeutics is 2.27 times more volatile than Blueprint Medicines Corp. It trades about 0.03 of its potential returns per unit of risk. Blueprint Medicines Corp is currently generating about 0.05 per unit of risk. If you would invest 366.00 in Inhibikase Therapeutics on September 12, 2024 and sell it today you would lose (46.00) from holding Inhibikase Therapeutics or give up 12.57% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inhibikase Therapeutics vs. Blueprint Medicines Corp
Performance |
| Timeline |
| Inhibikase Therapeutics |
| Blueprint Medicines Corp |
Inhibikase Therapeutics and Blueprint Medicines Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inhibikase Therapeutics and Blueprint Medicines
The main advantage of trading using opposite Inhibikase Therapeutics and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.| Inhibikase Therapeutics vs. Equillium | Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Valneva SE ADR | Inhibikase Therapeutics vs. Vivani Medical |
| Blueprint Medicines vs. Terns Pharmaceuticals | Blueprint Medicines vs. Amylyx Pharmaceuticals | Blueprint Medicines vs. Acumen Pharmaceuticals | Blueprint Medicines vs. Inozyme Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Complementary Tools
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |